Price
$3.66
Decreased by -1.48%
Dollar Volume
1.75 M
ADR%
7.94
Earnings Report Date (estimate)
Mar 22, 23 (-0.69)
Market Cap.
138.46 M
Shares Float
32.39 M
Shares Outstanding
37.83 M
Beta
2.76
Price / Earnings
-2.06
BPR
79.17
20D Range
3.15 4.41
50D Range
2.76 4.41
200D Range
2.53 12.08
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 10, 22 -0.53
Decreased by -26.19%
-0.63
Increased by +15.87%
Aug 15, 22 -0.65
Decreased by -71.05%
-0.64
Decreased by -1.56%
May 12, 22 -0.56
Decreased by -124.00%
-0.55
Decreased by -1.82%
Mar 24, 22 -0.45
Decreased by -87.50%
-0.54
Increased by +16.67%
Nov 10, 21 -0.42
Increased by +62.50%
-0.50
Increased by +16.00%
Aug 16, 21 -0.38 -0.34
Decreased by -11.76%
May 13, 21 -0.25 -0.30
Increased by +16.67%
Mar 25, 21 -0.24 -0.40
Increased by +40.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-20.19 M
Decreased by -28.81%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-24.34 M
Decreased by -74.14%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-20.98 M
Decreased by -136.63%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-16.34 M
Decreased by -112.14%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-15.67 M
Decreased by -85.36%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-13.97 M
Decreased by -601.51%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-8.87 M
Decreased by -391.19%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-7.70 M
Decreased by -690.76%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.